GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenax Therapeutics Inc (FRA:YBO0) » Definitions » Total Equity

Tenax Therapeutics (FRA:YBO0) Total Equity : €11.44 Mil (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Tenax Therapeutics Total Equity?

Tenax Therapeutics's total equity for the quarter that ended in Mar. 2024 was €11.44 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Tenax Therapeutics Total Equity Historical Data

The historical data trend for Tenax Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenax Therapeutics Total Equity Chart

Tenax Therapeutics Annual Data
Trend Apr14 Apr15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.40 3.80 3.76 1.41 7.43

Tenax Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.34 12.20 10.58 7.43 11.44

Tenax Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Tenax Therapeutics's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=10.715-3.289
=7.43

Tenax Therapeutics's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=13.303-1.869
=11.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tenax Therapeutics Total Equity Related Terms

Thank you for viewing the detailed overview of Tenax Therapeutics's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Tenax Therapeutics (FRA:YBO0) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenax Therapeutics Inc (FRA:YBO0) » Definitions » Total Equity
Comparable Companies
PULM TFFP PTIX SCPX LGVN ENTO KTTA CVKD NTBL SIGY OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
TENX:USA
Address
101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Website
https://www.tenaxthera.com
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.

Tenax Therapeutics (FRA:YBO0) Headlines

No Headlines